Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Research & Development (2016 - 2025)

Palisade Bio (PALI) has disclosed Research & Development for 16 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 91.29% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$7.8 million, a 136.6% decrease, with the full-year FY2024 number at $9.1 million, up 31.48% from a year prior.
  • Research & Development was $1.4 million for Q3 2025 at Palisade Bio, down from $1.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $16.0 million in Q3 2024 to a low of -$11.8 million in Q4 2024.
  • A 5-year average of $1.6 million and a median of $1.4 million in 2025 define the central range for Research & Development.
  • Biggest YoY gain for Research & Development was 660.46% in 2024; the steepest drop was 3353.87% in 2024.
  • Palisade Bio's Research & Development stood at $314000.0 in 2021, then skyrocketed by 646.18% to $2.3 million in 2022, then plummeted by 84.55% to $362000.0 in 2023, then plummeted by 3353.87% to -$11.8 million in 2024, then soared by 111.83% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Research & Development are $1.4 million (Q3 2025), $1.7 million (Q2 2025), and $950000.0 (Q1 2025).